Filing Flows › Ocular Therapeutix (OCUL) › Q1 2026 › vs Q1 2025
Ocular Therapeutix (OCUL) Q1 2026 vs Q1 2025 (year over year)
Ocular Therapeutix's revenue rose $87K (+0.8%) from $10.7M in Q1 2025 to $10.8M in Q1 2026.
Ocular Therapeutix, Q1 2026: revenue $10.8M (+0.8% year over year), operating margin -865.5%, net loss $88.6M, operating cash flow −$66.0M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $10.8M | $10.7M | $87K | +0.8% |
| Other income, net | $4.7M | −$136K | $4.9M | — |
| Net loss | $88.6M | $64.1M | $24.6M | +38% |
| Costs & expenses | $104M | $74.8M | $29.4M | +39% |
| Operating costs | $104M | $74.6M | $29.5M | +40% |
| Cost of revenue | $1.3M | $1.3M | $67K | +5% |
| Research & development | $66.2M | $42.9M | $23.4M | +54% |
| Sales & marketing | $16.6M | $14.1M | $2.4M | +17% |
| General & admin | $20.0M | $16.3M | $3.7M | +22% |
| Operating cash sources | $88.6M | $64.1M | $24.6M | +38% |
| Depreciation & amortization | $1.3M | $981K | $302K | +31% |
| Share-based compensation | $15.6M | $10.5M | $5.1M | +49% |
| Working capital & other | $5.8M | $7.9M | −$2.2M | -28% |
| Cash used in operations | $66.0M | $44.7M | $21.3M | +48% |
| Net loss absorbed | $88.6M | $64.1M | $24.6M | +38% |
Questions
How much did Ocular Therapeutix's revenue grow year over year in Q1 2026?
Ocular Therapeutix's revenue rose $87K (+0.8%) from $10.7M in Q1 2025 to $10.8M in Q1 2026.